NovaBay Signs Distribution Agreement with McKesson for i-Lid Cleanser
November 17 2014 - 7:00AM
Business Wire
The agreement with the largest distributor of
pharmaceutical products in the U.S. will expand the availability of
NovaBay’s i-Lid-Cleanser to 45,000 pharmacies all across the
country
NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a
biopharmaceutical company focusing on the development and
commercialization of its non-antibiotic anti-infective products,
announced today that it has signed a nationwide distribution
agreement with McKesson Corporation (NYSE:MCK). The agreement
covers NovaBay’s i-LidTM Cleanser, a prescription lid and lash
hygiene product for the management of debilitating eye conditions
such as blepharitis, Meibomian gland dysfunction and associated dry
eye.
McKesson is the oldest and largest health care services company
in the nation, and is also the largest pharmaceutical distributor
in North America, providing products and supplies to 45,000
pharmacies. “Having i-Lid Cleanser now widely available in local
pharmacies and major retail chains across the U.S., such as
Wal-Mart, Costco, CVS and Target is another major achievement in
NovaBay’s commercialization strategy,” said Dr. Ron Najafi,
Chairman and CEO of NovaBay.
An estimated 30 million Americans suffer from chronic and often
painful eye conditions such as blepharitis and meibomian gland
dysfunction, which causes dry eye. This agreement will make i-Lid
Cleanser, which ophthalmologists and optometrists are now using to
successfully treat those conditions, readily available to those
patients.
NovaBay recently launched a major marketing effort with a
dedicated sales force for i-Lid Cleanser aimed at optometrists and
ophthalmologists. “The agreement with McKesson will make our sales
team much more effective, because eye care professionals now can be
assured that patients will be able to easily fill prescriptions for
i-Lid Cleanser,” added Glenn Moro, Vice President of Sales and
Marketing.
NovaBay’s i-Lid Cleanser is the only eye care product to contain
Neutrox™, NovaBay’s name for its proprietary pure hypochlorous acid
(HOCl). Labs tests show that Neutrox, a naturally occurring
substance released by white blood cells to fight microbial
invaders, has potent antimicrobial activity, yet is non-toxic to
mammalian cells. It also neutralizes bacterial toxins, and has been
cleared by the Food & Drug Administration to clean skin and
wounds.
As a result of its properties, i-Lid Cleanser is ideal for the
treatment of blepharitis, where Staphylcocci bacteria grow on
eyelids, causing swelling, redness, inflammation, irritation and a
crusty build-up, and dry eye syndrome. Patients who’ve had
blepharitis for years—along with their doctors—report i-Lid has
finally brought relief from the often-painful condition. Many eye
doctors are also now using i-Lid Cleanser routinely in preparation
for cataract surgery and other types of surgery, and to treat dry
eye syndrome. Because Neutrox is not a traditional antibiotic or
steroid, there are no risks of bacterial resistance or side
effects.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics® NovaBay Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on addressing the unmet
therapeutic needs of the global, topical anti-infective market with
its two distinct product categories: Aganocide® compounds, led by
auriclosene, and its Hypochlorous Solution Family of Products:
NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye
care market, and CelleRx™ for the dermatology market.
Stay informed on NovaBay's
progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website
Forward-looking Statements This release contains
forward-looking statements, which are based upon management’s
current expectations, assumptions, estimates, projections and
beliefs. These statements include, but are not limited to,
statements regarding the future distribution of i-Lid Cleanser, the
clinical efficacy of i-Lid Cleanser, and i-Lid Cleanser’s
contribution toward the company’s expected future financial
results. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results or achievements to be materially different and adverse from
those expressed in or implied by the forward-looking statements.
Factors that might cause or contribute to such differences include,
but are not limited to, risks and uncertainties relating to
difficulties or delays in product development, clinical trials,
regulatory approval, production and marketing of the company’s
products, unexpected adverse side effects or inadequate therapeutic
efficacy of the product candidates, the uncertainty of patent
protection for the company’s intellectual property or trade
secrets, the company’s ability to obtain additional financing as
necessary and unanticipated research and development and other
costs. Other risks relating to the company and its products,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
NovaBayFor NovaBay i-Lid Cleanser purchasing information,
please contact:Email usCall us:
1-800-890-0329www.ilidcleanser.comorFor investor information,
please contact:Thomas J. Paulson, 510-899-8809Chief Financial
OfficerContact T. Paulson
McKesson (NYSE:MCK)
Historical Stock Chart
From Aug 2024 to Sep 2024
McKesson (NYSE:MCK)
Historical Stock Chart
From Sep 2023 to Sep 2024